Clinical site monitoring in human subjects for an extramural study to assess dermal pharmacokinetic (PK) and systemic PK under maximum exposure conditions of lidocaine/prilocaine cream to evaluate the…
Ended Awarded Last action
- Contract number
- 75F40122F19028
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $9,003
Award facts
- Contract value 100% obligated
- $9,003.01 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$3,191 | |
| Original award | $12,194 |
About this award
This federal contract award is for CLINICAL SITE MONITORING IN HUMAN SUBJECTS FOR AN EXTRAMURAL STUDY TO ASSESS DERMAL PHARMACOKINETIC (PK) AND SYSTEMIC PK UNDER MAXIMUM EXPOSURE CONDITIONS OF LIDOCAINE/PRILOCAINE CREAM TO EVALUATE THE DERMAL-SYSTEMIC CROSSTALK at Joanneum Research, G. The prime contractor is The Emmes Company LLC, a global clinical research organization that provides a wide range of services to support clinical trials and research programs for federal agencies, particularly the National Institutes of Health (NIH). The award, issued by the Food and Drug Administration (FDA), a civilian agency, has a ceiling value of $9,003.01 and a firm fixed-price pricing type. The ultimate completion date is August 8, 2023. This contract award is not set aside for a specific business type. The Emmes Company LLC has secured multiple prime and sub-awards from various NIH institutes, including the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute on Drug Abuse, demonstrating its expertise in supporting complex research initiatives.
Description
Clinical site monitoring in human subjects for an extramural study to assess dermal pharmacokinetic (PK) and systemic PK under maximum exposure conditions of lidocaine/prilocaine cream to evaluate the dermal-systemic crosstalk at joanneum research, g
Quick answers
Who was awarded contract 75F40122F19028?
75F40122F19028 was awarded to The Emmes Company, LLC by Food and Drug Administration (Department of Health and Human Services) on August 9, 2022.
How much is contract 75F40122F19028 worth?
The government has obligated $9,003 on 75F40122F19028.
Is contract 75F40122F19028 an order under another contract?
Yes. 75F40122F19028 is a delivery order under HHSF223201710031I, an indefinite delivery contract.
Was contract 75F40122F19028 competed?
The extent of competition for 75F40122F19028 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award